cd45 1 mice Search Results


90
POSTECH Inc cd45.1 wt mice
Cd45.1 Wt Mice, supplied by POSTECH Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd45+1+mice/cd45+1+2+b6+mice/pm39630890-277-3-24
Average 90 stars, based on 1 article reviews
cd45.1 wt mice - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
CasGene Biotech Co Ltd cd45.1 mice (referred to as b6.sjl-ptprca pepcb /boyj)
Cd45.1 Mice (Referred To As B6.Sjl Ptprca Pepcb /Boyj), supplied by CasGene Biotech Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd45+1+mice/cd45+1+mice++referred+to+as+b6+sjl+ptprca+pepcb++boyj+/pm39075283-377-0-11
Average 90 stars, based on 1 article reviews
cd45.1 mice (referred to as b6.sjl-ptprca pepcb /boyj) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Amrep Inc cd45.1 mice
Cd45.1 Mice, supplied by Amrep Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd45+1+mice/cd45+1+mice/pmc08517849-129-3-13
Average 90 stars, based on 1 article reviews
cd45.1 mice - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Jax Inc b6.sjl-ptprca pepcb/boyj (cd45.1+) f1 mice
B6.Sjl Ptprca Pepcb/Boyj (Cd45.1+) F1 Mice, supplied by Jax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd45+1+mice/b6+sjl+ptprca+pepcb+boyj++cd45+1+++f1+mice/ppr0460638-191-13-16
Average 90 stars, based on 1 article reviews
b6.sjl-ptprca pepcb/boyj (cd45.1+) f1 mice - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
StemCells Inc lks population (containing stem and uncommitted progenitors) from the bone marrow of b6ly5.1 mice (cd45.1 alloantigen)
Lks Population (Containing Stem And Uncommitted Progenitors) From The Bone Marrow Of B6ly5.1 Mice (Cd45.1 Alloantigen), supplied by StemCells Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd45+1+mice/lks+population++containing+stem+and+uncommitted+progenitors++from+the+bone+marrow+of+b6ly5+1+mice++cd45+1+alloantigen+/pm22511319-124-39-26
Average 90 stars, based on 1 article reviews
lks population (containing stem and uncommitted progenitors) from the bone marrow of b6ly5.1 mice (cd45.1 alloantigen) - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Rocha labs cd45.1 cd3 -/- mice
Cd45.1 Cd3 / Mice, supplied by Rocha labs, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd45+1+mice/cd45+1+cd3+++++mice/pmc07907429__mmc1-32-3-12
Average 90 stars, based on 1 article reviews
cd45.1 cd3 -/- mice - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

90
Schering-Plough corporation il23ra −/− otii+cd45.1+ mice
(a) Clinical scores of Il23ra−/−, Il23ra+/− and Il23ra+/+ mice after EAE induction. (b) Clinical scores of mixed bone marrow chimeras following EAE induction. Donor bone marrow genotype is indicated. (c) Flow cytometry of CD4+ cells obtained from the CNS of mixed bone marrow chimeras 11 days post-EAE induction. Genotype of each population is indicated. (d) Proportion of <t>wild-type</t> <t>CD45.1+</t> or Il23ra−/− CD45.1− CD4+ T cells in the CNS of mixed bone marrow chimeras at indicated time points; data is expressed as mean ratio ± s.d. of CD45.1− to CD45.1+ CD4+ T (wild-type) cells. (e) Absolute numbers of CD4+ T cells in the CNS on day 9 (pre-onset) and day 11 (onset of clinical signs) of EAE. Data shown are each representative of three experiments with 5 mice per group.
Il23ra −/− Otii+Cd45.1+ Mice, supplied by Schering-Plough corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd45+1+mice/il23ra+++++otii+cd45+1++mice/pmc02945605-425-2-7
Average 90 stars, based on 1 article reviews
il23ra −/− otii+cd45.1+ mice - by Bioz Stars, 2026-10
90/100 stars
  Buy from Supplier

86
Shanghai Model Organisms Center cd45 1 mice
(a) Clinical scores of Il23ra−/−, Il23ra+/− and Il23ra+/+ mice after EAE induction. (b) Clinical scores of mixed bone marrow chimeras following EAE induction. Donor bone marrow genotype is indicated. (c) Flow cytometry of CD4+ cells obtained from the CNS of mixed bone marrow chimeras 11 days post-EAE induction. Genotype of each population is indicated. (d) Proportion of <t>wild-type</t> <t>CD45.1+</t> or Il23ra−/− CD45.1− CD4+ T cells in the CNS of mixed bone marrow chimeras at indicated time points; data is expressed as mean ratio ± s.d. of CD45.1− to CD45.1+ CD4+ T (wild-type) cells. (e) Absolute numbers of CD4+ T cells in the CNS on day 9 (pre-onset) and day 11 (onset of clinical signs) of EAE. Data shown are each representative of three experiments with 5 mice per group.
Cd45 1 Mice, supplied by Shanghai Model Organisms Center, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd45+1+mice/1+cd45+mice/pmc12592349-237-3-8
Average 86 stars, based on 1 article reviews
cd45 1 mice - by Bioz Stars, 2026-10
86/100 stars
  Buy from Supplier

Image Search Results


(a) Clinical scores of Il23ra−/−, Il23ra+/− and Il23ra+/+ mice after EAE induction. (b) Clinical scores of mixed bone marrow chimeras following EAE induction. Donor bone marrow genotype is indicated. (c) Flow cytometry of CD4+ cells obtained from the CNS of mixed bone marrow chimeras 11 days post-EAE induction. Genotype of each population is indicated. (d) Proportion of wild-type CD45.1+ or Il23ra−/− CD45.1− CD4+ T cells in the CNS of mixed bone marrow chimeras at indicated time points; data is expressed as mean ratio ± s.d. of CD45.1− to CD45.1+ CD4+ T (wild-type) cells. (e) Absolute numbers of CD4+ T cells in the CNS on day 9 (pre-onset) and day 11 (onset of clinical signs) of EAE. Data shown are each representative of three experiments with 5 mice per group.

Journal:

Article Title: Interleukin 23 receptor is essential for terminal differentiation of effector T helper type 17 cells in vivo

doi: 10.1038/ni.1698

Figure Lengend Snippet: (a) Clinical scores of Il23ra−/−, Il23ra+/− and Il23ra+/+ mice after EAE induction. (b) Clinical scores of mixed bone marrow chimeras following EAE induction. Donor bone marrow genotype is indicated. (c) Flow cytometry of CD4+ cells obtained from the CNS of mixed bone marrow chimeras 11 days post-EAE induction. Genotype of each population is indicated. (d) Proportion of wild-type CD45.1+ or Il23ra−/− CD45.1− CD4+ T cells in the CNS of mixed bone marrow chimeras at indicated time points; data is expressed as mean ratio ± s.d. of CD45.1− to CD45.1+ CD4+ T (wild-type) cells. (e) Absolute numbers of CD4+ T cells in the CNS on day 9 (pre-onset) and day 11 (onset of clinical signs) of EAE. Data shown are each representative of three experiments with 5 mice per group.

Article Snippet: Il23ra −/− OTII+CD45.1+ mice were generated at Schering Plough Biopharma.

Techniques: Flow Cytometry

(a) Frequency of wild-type or Il23ra−/− CD45.1+CD4+OTII T cells, expressed as percentage of total CD4+ T cells (mean ± s.d), following transfer into wild-type recipients and immunization with OVA(323–339). (b) Delayed type hypersensitivity reaction in mice after transfer of wild-type or Il23ra−/− OTII cells. The increase in foot thickness over the contralateral saline-challenged foot is shown. (c) Time course of Intracellular IL-17 in OTII cells from dLN assessed by flow cytometry after ex vivo stimulation with PMA + ionomycin on indicated days post-immunization. (d) Intracellular Foxp3 expression in OTII cells assessed on days 5 and 7 post-immunization (e) Flow cytometry for phosphorylated STAT3 in OTII cells after 15 minute stimulation with indicated cytokines 4 days post-immunization. (f) Flow cytometry of Cre-deleted Stat3flox/flox CD4+ cells following second stimulation with anti-CD3 in the presence of IL-23. IL-17 is shown as percentage of GFP+ and GFP− cells on each plot. All data shown are representative of at least 3 independent experiments having 4 to 5 mice per group.

Journal:

Article Title: Interleukin 23 receptor is essential for terminal differentiation of effector T helper type 17 cells in vivo

doi: 10.1038/ni.1698

Figure Lengend Snippet: (a) Frequency of wild-type or Il23ra−/− CD45.1+CD4+OTII T cells, expressed as percentage of total CD4+ T cells (mean ± s.d), following transfer into wild-type recipients and immunization with OVA(323–339). (b) Delayed type hypersensitivity reaction in mice after transfer of wild-type or Il23ra−/− OTII cells. The increase in foot thickness over the contralateral saline-challenged foot is shown. (c) Time course of Intracellular IL-17 in OTII cells from dLN assessed by flow cytometry after ex vivo stimulation with PMA + ionomycin on indicated days post-immunization. (d) Intracellular Foxp3 expression in OTII cells assessed on days 5 and 7 post-immunization (e) Flow cytometry for phosphorylated STAT3 in OTII cells after 15 minute stimulation with indicated cytokines 4 days post-immunization. (f) Flow cytometry of Cre-deleted Stat3flox/flox CD4+ cells following second stimulation with anti-CD3 in the presence of IL-23. IL-17 is shown as percentage of GFP+ and GFP− cells on each plot. All data shown are representative of at least 3 independent experiments having 4 to 5 mice per group.

Article Snippet: Il23ra −/− OTII+CD45.1+ mice were generated at Schering Plough Biopharma.

Techniques: Flow Cytometry, Ex Vivo, Expressing

(a–e) Analysis of phenotype of wild-type or Il23ra−/− CD45.1+CD4+OTII T cells after transfer into wild-type recipients and immunization with OVA(323–339). (a) Flow cytometry for cell surface expression of CD44, CCR7 and CD62L on wild-type and Il23ra−/− OTII T cells (shaded histograms) overlaid with total CD4+ cells for comparison (clear histograms) at day 7 post-immunization. b) Surface IL-7Rα expression on wild-type (shaded histogram) and Il23ra−/− (clear histogram) OTII cells from dLN. c) RT-PCR analysis of IL-7Rα expression in OTII+ cells sorted by flow cytometry from dLN; values are normalized to ubiquitin expression. As a control, total OTII–CD4+ cells were isolated at the same time from recipients of the indicated OTII cells. Data shown are mean ± s.d. of two groups of samples each containing 5 mice per condition. d) Surface CD27 expression on OTII cells in dLN and blood. e) Frequency of wild-type and Il23ra−/− OTII cells (as proportion of total CD4+ cells) in blood at indicated time points post immunization. Data shown are representative of 3 experiments with similar results.

Journal:

Article Title: Interleukin 23 receptor is essential for terminal differentiation of effector T helper type 17 cells in vivo

doi: 10.1038/ni.1698

Figure Lengend Snippet: (a–e) Analysis of phenotype of wild-type or Il23ra−/− CD45.1+CD4+OTII T cells after transfer into wild-type recipients and immunization with OVA(323–339). (a) Flow cytometry for cell surface expression of CD44, CCR7 and CD62L on wild-type and Il23ra−/− OTII T cells (shaded histograms) overlaid with total CD4+ cells for comparison (clear histograms) at day 7 post-immunization. b) Surface IL-7Rα expression on wild-type (shaded histogram) and Il23ra−/− (clear histogram) OTII cells from dLN. c) RT-PCR analysis of IL-7Rα expression in OTII+ cells sorted by flow cytometry from dLN; values are normalized to ubiquitin expression. As a control, total OTII–CD4+ cells were isolated at the same time from recipients of the indicated OTII cells. Data shown are mean ± s.d. of two groups of samples each containing 5 mice per condition. d) Surface CD27 expression on OTII cells in dLN and blood. e) Frequency of wild-type and Il23ra−/− OTII cells (as proportion of total CD4+ cells) in blood at indicated time points post immunization. Data shown are representative of 3 experiments with similar results.

Article Snippet: Il23ra −/− OTII+CD45.1+ mice were generated at Schering Plough Biopharma.

Techniques: Flow Cytometry, Expressing, Reverse Transcription Polymerase Chain Reaction, Isolation

(a–d) Intracellular cytokine analysis of wild-type or Il23ra−/− CD45.1+CD4+OTII T cells after transfer into wild-type recipients and immunization with OVA(323–339). (a) Intracellular staining of IL-17 and IL-2 in dLN OTII cells (b) Mean frequency of IL-17+IL-2− cells as proportion of CD4+OTII cells at indicated time points post-immunization. (c) Mean frequency of IL-2+IL-17− cells as proportion of CD4+OTII cells at indicated time points post-immunization. (d) Intracellular staining of IL-17 and IL-2 in blood OTII. Data shown are representative of 4 independent experiments with 4 mice per group.

Journal:

Article Title: Interleukin 23 receptor is essential for terminal differentiation of effector T helper type 17 cells in vivo

doi: 10.1038/ni.1698

Figure Lengend Snippet: (a–d) Intracellular cytokine analysis of wild-type or Il23ra−/− CD45.1+CD4+OTII T cells after transfer into wild-type recipients and immunization with OVA(323–339). (a) Intracellular staining of IL-17 and IL-2 in dLN OTII cells (b) Mean frequency of IL-17+IL-2− cells as proportion of CD4+OTII cells at indicated time points post-immunization. (c) Mean frequency of IL-2+IL-17− cells as proportion of CD4+OTII cells at indicated time points post-immunization. (d) Intracellular staining of IL-17 and IL-2 in blood OTII. Data shown are representative of 4 independent experiments with 4 mice per group.

Article Snippet: Il23ra −/− OTII+CD45.1+ mice were generated at Schering Plough Biopharma.

Techniques: Staining

(a–b) Intracellular cytokine analysis of wild-type or Il23ra−/− CD45.1+CD4+OTII T cells after transfer into wild-type recipients and immunization with OVA(323–339). a) Frequency of IFN-γ+IL-17− cells as a proportion of CD4+OTII cells on indicated days post-immunization. b) Frequency of IFN-γ+IL-17+ cells as a proportion of CD4+ OTII cells on indicated days post-immunization. Data shown are representative of 3 independent experiments with 5 mice per group. (c–e) Wild-type and Il23ra−/− mice were infected with T. gondii and then followed for survival (c); frequency of IFN-γ+CD4+ cells following ex vivo stimulation of dLN cells from mice 9 days post-infection were also evaluated (d). (e) Intracellular flow cytometry of IFN-γ and IL-2 production by CD4+ cells following ex vivo stimulation of dLN cells from mice 9 days post-infection Data shown are representative of two independent experiments (5 mice per group) with similar results.

Journal:

Article Title: Interleukin 23 receptor is essential for terminal differentiation of effector T helper type 17 cells in vivo

doi: 10.1038/ni.1698

Figure Lengend Snippet: (a–b) Intracellular cytokine analysis of wild-type or Il23ra−/− CD45.1+CD4+OTII T cells after transfer into wild-type recipients and immunization with OVA(323–339). a) Frequency of IFN-γ+IL-17− cells as a proportion of CD4+OTII cells on indicated days post-immunization. b) Frequency of IFN-γ+IL-17+ cells as a proportion of CD4+ OTII cells on indicated days post-immunization. Data shown are representative of 3 independent experiments with 5 mice per group. (c–e) Wild-type and Il23ra−/− mice were infected with T. gondii and then followed for survival (c); frequency of IFN-γ+CD4+ cells following ex vivo stimulation of dLN cells from mice 9 days post-infection were also evaluated (d). (e) Intracellular flow cytometry of IFN-γ and IL-2 production by CD4+ cells following ex vivo stimulation of dLN cells from mice 9 days post-infection Data shown are representative of two independent experiments (5 mice per group) with similar results.

Article Snippet: Il23ra −/− OTII+CD45.1+ mice were generated at Schering Plough Biopharma.

Techniques: Infection, Ex Vivo, Flow Cytometry